US Food and Drug Administration (FDA) officials asserted at a 26 April Generic Drug Forum (GDF) that firms with weak quality cultures are more susceptible to submit abbreviated new drug applications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results